Y Nadler1, A M González2, R L Camp3, D L Rimm3, H M Kluger1, Y Kluger4. 1. Department of Medicine, Yale University School of Medicine, New Haven, CT. 2. Department of Cell Biology, New York University, New York, NY; Computer Science Department, Universidad Autónoma de Madrid, Madrid, Spain. 3. Department of Pathology, Yale University School of Medicine, New Haven, USA. 4. Department of Cell Biology, New York University, New York, NY. Electronic address: kluger@saturn.med.nyu.edu.
Abstract
BACKGROUND: Growth factor receptor-bound protein-7 (Grb7) is an adapter-type signaling protein recruited to various tyrosine kinases, including HER2/neu. Grb7-specific inhibitors are in early development. As with other targeted therapies, response to therapy might be associated with target expression. MATERIALS AND METHODS: Tissue microarrays containing 638 primary breast cancer specimens with 15-year patient follow-up were employed to assess Grb7 expression using our Automated QUantitative Analysis method; cytokeratin defines pixels as breast cancer (tumor mask) within the histospot, and Grb7 expression within the mask is measured with Cy5-conjugated antibodies. RESULTS: High Grb7 expression was strongly associated with decreased survival in the entire cohort and in the node-positive subset (P = 0.0034 and P = 0.0019, respectively). On multivariable analysis, it remained an independent prognostic marker (P = 0.01). High Grb7 was strongly associated with high HER2/neu, and coexpression of these molecules was associated with worse prognosis than HER2/neu overexpression alone. CONCLUSIONS: High Grb7 defines a subset of breast cancer patients with decreased survival, indicating that Grb7 might be a valuable prognostic marker and drug target. Coexpression with HER2/neu indicates that cotargeting these molecules might be an effective approach for treating HER2/neu-positive breast cancers. Future studies using Grb7-targeting agents should include assessment of Grb7 levels.
BACKGROUND:Growth factor receptor-bound protein-7 (Grb7) is an adapter-type signaling protein recruited to various tyrosine kinases, including HER2/neu. Grb7-specific inhibitors are in early development. As with other targeted therapies, response to therapy might be associated with target expression. MATERIALS AND METHODS: Tissue microarrays containing 638 primary breast cancer specimens with 15-year patient follow-up were employed to assess Grb7 expression using our Automated QUantitative Analysis method; cytokeratin defines pixels as breast cancer (tumor mask) within the histospot, and Grb7 expression within the mask is measured with Cy5-conjugated antibodies. RESULTS: High Grb7 expression was strongly associated with decreased survival in the entire cohort and in the node-positive subset (P = 0.0034 and P = 0.0019, respectively). On multivariable analysis, it remained an independent prognostic marker (P = 0.01). High Grb7 was strongly associated with high HER2/neu, and coexpression of these molecules was associated with worse prognosis than HER2/neu overexpression alone. CONCLUSIONS: High Grb7 defines a subset of breast cancerpatients with decreased survival, indicating that Grb7 might be a valuable prognostic marker and drug target. Coexpression with HER2/neu indicates that cotargeting these molecules might be an effective approach for treating HER2/neu-positive breast cancers. Future studies using Grb7-targeting agents should include assessment of Grb7 levels.
Authors: Nigus D Ambaye; Menachem J Gunzburg; Daouda A K Traore; Mark P Del Borgo; Patrick Perlmutter; Matthew C J Wilce; Jacqueline A Wilce Journal: Acta Crystallogr F Struct Biol Commun Date: 2014-01-21 Impact factor: 1.056
Authors: Amal Said Darweesh; Manal Louis Louka; Maha Hana; Shaymaa Rashad; Mohamed El-Shinawi; Ahmed Sharaf-Eldin; Samar Kamal Kassim Journal: Med Oncol Date: 2014-09-03 Impact factor: 3.064
Authors: Charlotte I Stroes; Sandor Schokker; Aafke Creemers; Remco J Molenaar; Maarten C C M Hulshof; Stephanie O van der Woude; Roel J Bennink; Ron A A Mathôt; Kausilia K Krishnadath; Cornelis J A Punt; Rob H A Verhoeven; Martijn G H van Oijen; Geert-Jan Creemers; Grard A P Nieuwenhuijzen; Maurice J C van der Sangen; Laurens V Beerepoot; Joos Heisterkamp; Maartje Los; Marije Slingerland; Annemieke Cats; Geke A P Hospers; Maarten F Bijlsma; Mark I van Berge Henegouwen; Sybren L Meijer; Hanneke W M van Laarhoven Journal: J Clin Oncol Date: 2019-12-06 Impact factor: 44.544